Table 1.
Study Cytology | ||||||||
---|---|---|---|---|---|---|---|---|
Referral Cytology |
Statistics | NILM | ASC-US | LSIL | ASC-H | HSIL+ | Missing | Total |
ASC-US | N | 54 | 30 | 22 | 19 | 12 | 3 | 140 |
p16/ki-67+ | 14 (25.93%) | 8 (26.67%) | 16 (72.73%) | 16 (84.21%) | 12 (100%) | 1 (33.33%) | 67 (47.86%) | |
CIN2+ | 4 (7.41%) | 2 (6.67%) | 8 (36.36%) | 9 (47.37%) | 10 (83.33%) | 0 (0%) | 33 (23.57%) | |
CIN3+ | 1 (1.85%) | 1 (3.33%) | 2 (9.09%) | 5 (26.32%) | 3 (25%) | 0 (0%) | 12 (8.57%) | |
LSIL | N | 49 | 53 | 88 | 21 | 45 | 8 | 264 |
p16/ki-67+ | 10 (20.41%) | 23 (43.40%) | 58 (65.91%) | 17 (80.95%) | 42 (93.33%) | 2 (25%) | 152 (57.58%) | |
CIN2+ | 4 (8.16%) | 6 (11.32%) | 31 (35.23%) | 12 (57.14%) | 36 (80%) | 2 (25%) | 91 (34.47%) | |
CIN3+ | 0 (0%) | 2 (3.77%) | 5 (5.68%) | 1 (4.76%) | 11 (24.44%) | 1 (12.50%) | 20 (7.58%) | |
ASC-H | N | 18 | 21 | 14 | 10 | 15 | 1 | 79 |
p16/ki-67 | 1 (5.56%) | 10 (47.62%) | 12 (85.71%) | 9 (90%) | 15 (100%) | 1 (100%) | 48 (60.76%) | |
CIN2+ | 4 (22.2%) | 4 (19.05%) | 10 (71.43%) | 5 (50%) | 15 (100%) | 1 (100%) | 39 (49.37%) | |
CIN3+ | 1 (5.56%) | 1 (4.76%) | 1 (7.14%) | 2 (20%) | 5 (33.33%) | 1 (100%) | 10 (12.66%) | |
HSIL+ | N | 13 | 8 | 11 | 11 | 70 | 1 | 114 |
p16/ki-67+ | 3 (23.08%) | 3 (37.50%) | 8 (72.73%) | 9 (81.82%) | 68 (87.14%) | 1 (100%) | 92 (80.70) | |
CIN2+ | 3 (23.08%) | 3 (37.50%) | 7 (63.64%) | 7 (63.64%) | 63 (90.00%) | 1 (100%) | 84 (73.68%) | |
CIN3+ | 0 (0%) | 0 (0%) | 3 (27.27%) | 4 (36.36%) | 34 (48.57%) | 0 (0%) | 41 (35.96%) | |
Missing | N | 9 | 5 | 3 | 2 | 9 | 0 | 28 |
p16/ki-67+ | 0 (0%) | 3 (60%) | 1 (33.33%) | 1 (50%) | 7 (77.78%) | 0 (0%) | 12 (42.86%) | |
CIN2+ | 0 (0%) | 1 (20%) | 0 (0%) | 1 (50%) | 9 (100%) | 0 (0%) | 11 (39.29%) | |
CIN3+ | 0 (0%) | 0 (0%0 | 0 (0%) | 0 (0%) | 5 (55.56%) | 0 (0%) | 5 (17.86%) | |
Total | N | 143 | 117 | 138 | 63 | 151 | 13 | 625 |
p16/ki-67+ | 28 (19.58%) | 47 (40.17%) | 95 (68.84%) | 52 (82.54%) | 144 (95.36%) | 5 (38.46%) | 371 (59.36%) | |
CIN2+ | 15 (10.49%) | 16 (13.68%) | 56 (40.58%) | 34 (53.97%) | 133 (88.08%) | 4 (30.77%) | 258 (41.28%) | |
CIN3+ | 2 (1.40%) | 4 (3.42%) | 11 (7.97%) | 12 (19.05%) | 58 (38.41%) | 1 (7.69%) | 88 (14.08%) |